UA32462U - Способ оценки эффективности коррекции нарушений микробиоценоза кишечника у детей младшего возраста с атопическим дерматитом - Google Patents
Способ оценки эффективности коррекции нарушений микробиоценоза кишечника у детей младшего возраста с атопическим дерматитом Download PDFInfo
- Publication number
- UA32462U UA32462U UAU200801899U UAU200801899U UA32462U UA 32462 U UA32462 U UA 32462U UA U200801899 U UAU200801899 U UA U200801899U UA U200801899 U UAU200801899 U UA U200801899U UA 32462 U UA32462 U UA 32462U
- Authority
- UA
- Ukraine
- Prior art keywords
- correction
- children
- effectiveness
- coprofiltrates
- intestines
- Prior art date
Links
- 238000012937 correction Methods 0.000 title claims abstract description 37
- 206010012438 Dermatitis atopic Diseases 0.000 title claims abstract description 22
- 201000008937 atopic dermatitis Diseases 0.000 title claims abstract description 22
- 238000000034 method Methods 0.000 title claims abstract description 9
- 210000000936 intestine Anatomy 0.000 title abstract description 6
- 238000011156 evaluation Methods 0.000 title abstract description 3
- 208000027244 Dysbiosis Diseases 0.000 claims abstract description 10
- 230000007140 dysbiosis Effects 0.000 claims abstract description 10
- 230000008029 eradication Effects 0.000 claims abstract description 8
- 208000036649 Dysbacteriosis Diseases 0.000 claims abstract description 6
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims abstract description 5
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 claims abstract description 5
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 claims abstract description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 30
- 230000000968 intestinal effect Effects 0.000 claims description 26
- 229920002683 Glycosaminoglycan Polymers 0.000 claims description 12
- 244000005709 gut microbiome Species 0.000 claims description 5
- 244000005706 microflora Species 0.000 abstract description 7
- 230000001717 pathogenic effect Effects 0.000 abstract description 4
- 210000003608 fece Anatomy 0.000 abstract description 3
- 208000035475 disorder Diseases 0.000 description 22
- 239000000203 mixture Substances 0.000 description 7
- 241000186000 Bifidobacterium Species 0.000 description 6
- 230000000699 topical effect Effects 0.000 description 6
- 241000588724 Escherichia coli Species 0.000 description 5
- 241000186660 Lactobacillus Species 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 235000013406 prebiotics Nutrition 0.000 description 5
- 208000010201 Exanthema Diseases 0.000 description 4
- 201000008225 Klebsiella pneumonia Diseases 0.000 description 4
- 241000588747 Klebsiella pneumoniae Species 0.000 description 4
- 206010035717 Pneumonia klebsiella Diseases 0.000 description 4
- 241000191967 Staphylococcus aureus Species 0.000 description 4
- 201000005884 exanthem Diseases 0.000 description 4
- 206010037844 rash Diseases 0.000 description 4
- 230000013872 defecation Effects 0.000 description 3
- 230000005713 exacerbation Effects 0.000 description 3
- 230000000774 hypoallergenic effect Effects 0.000 description 3
- 210000003097 mucus Anatomy 0.000 description 3
- 210000001364 upper extremity Anatomy 0.000 description 3
- ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- ICKFFNBDFNZJSX-UHFFFAOYSA-N N'-[(4-chlorophenyl)methyl]-N,N-dimethyl-N'-(2-pyridinyl)ethane-1,2-diamine Chemical compound C=1C=CC=NC=1N(CCN(C)C)CC1=CC=C(Cl)C=C1 ICKFFNBDFNZJSX-UHFFFAOYSA-N 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 208000001431 Psychomotor Agitation Diseases 0.000 description 2
- 206010037876 Rash papular Diseases 0.000 description 2
- 206010038743 Restlessness Diseases 0.000 description 2
- 241000295644 Staphylococcaceae Species 0.000 description 2
- 208000019790 abdominal distention Diseases 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 210000000544 articulatio talocruralis Anatomy 0.000 description 2
- 230000000721 bacterilogical effect Effects 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000000748 cardiovascular system Anatomy 0.000 description 2
- 229960001803 cetirizine Drugs 0.000 description 2
- 230000035606 childbirth Effects 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000002310 elbow joint Anatomy 0.000 description 2
- 239000003974 emollient agent Substances 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 230000002550 fecal effect Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 235000021384 green leafy vegetables Nutrition 0.000 description 2
- 230000002949 hemolytic effect Effects 0.000 description 2
- 230000000544 hyperemic effect Effects 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 210000000629 knee joint Anatomy 0.000 description 2
- 108010006741 lactobacterin Proteins 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- DALKLAYLIPSCQL-YPYQNWSCSA-N methylprednisolone aceponate Chemical compound C1([C@@H](C)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@@](C(=O)COC(C)=O)(OC(=O)CC)[C@@]2(C)C[C@@H]1O DALKLAYLIPSCQL-YPYQNWSCSA-N 0.000 description 2
- 229960002037 methylprednisolone aceponate Drugs 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 210000003739 neck Anatomy 0.000 description 2
- 208000012963 papular rash Diseases 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 239000006041 probiotic Substances 0.000 description 2
- 235000018291 probiotics Nutrition 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000003857 wrist joint Anatomy 0.000 description 2
- 206010003645 Atopy Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000031662 Noncommunicable disease Diseases 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009285 allergic inflammation Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 230000001120 cytoprotective effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- 210000001842 enterocyte Anatomy 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 230000004130 lipolysis Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 230000001936 parietal effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 231100000255 pathogenic effect Toxicity 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 231100000046 skin rash Toxicity 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Способ оценки эффективности коррекции нарушений микробиоценоза кишечника у детей младшего возраста с атопическим дерматитом включает анализ кала на дисбактериоз. Определяют уровень гликозаминогликанов и свободной фукозы в копрофильтратах до коррекции и после коррекции нарушений микробиоценоза кишечника и, если после проведенной коррекции уровень гликозаминогликанов и свободной фукозы в копрофильтратах ниже не меньше чем в 1,5 раза предыдущего, то диагностируют эрадикацию условно-патогенной микрофлоры кишечника и эффективную коррекцию выявленных нарушений.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| UAU200801899U UA32462U (ru) | 2008-02-14 | 2008-02-14 | Способ оценки эффективности коррекции нарушений микробиоценоза кишечника у детей младшего возраста с атопическим дерматитом |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| UAU200801899U UA32462U (ru) | 2008-02-14 | 2008-02-14 | Способ оценки эффективности коррекции нарушений микробиоценоза кишечника у детей младшего возраста с атопическим дерматитом |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA32462U true UA32462U (ru) | 2008-05-12 |
Family
ID=39820507
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAU200801899U UA32462U (ru) | 2008-02-14 | 2008-02-14 | Способ оценки эффективности коррекции нарушений микробиоценоза кишечника у детей младшего возраста с атопическим дерматитом |
Country Status (1)
| Country | Link |
|---|---|
| UA (1) | UA32462U (ru) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2467174C2 (ru) * | 2011-02-25 | 2012-11-20 | Александр Васильевич Иванов | Поршневая машина |
| EP3268019A4 (en) * | 2015-03-13 | 2018-10-31 | Evolve Biosystems, Inc. | Compositions that metabolize or sequester free sugar monomers and uses thereof |
| US10716816B2 (en) | 2014-10-24 | 2020-07-21 | Evolve Biosystems Inc. | Activated bifidobacteria and methods of use thereof |
-
2008
- 2008-02-14 UA UAU200801899U patent/UA32462U/ru unknown
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2467174C2 (ru) * | 2011-02-25 | 2012-11-20 | Александр Васильевич Иванов | Поршневая машина |
| US10716816B2 (en) | 2014-10-24 | 2020-07-21 | Evolve Biosystems Inc. | Activated bifidobacteria and methods of use thereof |
| EP3268019A4 (en) * | 2015-03-13 | 2018-10-31 | Evolve Biosystems, Inc. | Compositions that metabolize or sequester free sugar monomers and uses thereof |
| AU2016233529B2 (en) * | 2015-03-13 | 2022-03-10 | Evolve Biosystems, Inc. | Compositions that metabolize or sequester free sugar monomers and uses thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Dissanayake et al. | Skin care and synbiotics for prevention of atopic dermatitis or food allergy in newborn infants: a 2× 2 factorial, randomized, non-treatment controlled trial | |
| Taylor et al. | Probiotic supplementation for the first 6 months of life fails to reduce the risk of atopic dermatitis and increases the risk of allergen sensitization in high-risk children: a randomized controlled trial | |
| Puccio et al. | Clinical evaluation of a new starter formula for infants containing live Bifidobacterium longum BL999 and prebiotics | |
| Arslanoglu et al. | Early Neutral Prebiotic Oligosaccharide Supplentation reduces the incidence of some allergic manifestations in the first 5 years of life | |
| Coccorullo et al. | Lactobacillus reuteri (DSM 17938) in infants with functional chronic constipation: a double-blind, randomized, placebo-controlled study | |
| Sandini et al. | Protective and risk factors for allergic diseases in high-risk children at the ages of two and five years | |
| Tateyama et al. | Effect of xylooligosaccharide intake on severe constipation in pregnant women | |
| Mills et al. | Efficacy of Bifidobacterium longum alone or in multi-strain probiotic formulations during early life and beyond | |
| Marshall et al. | Predictors for snoring in children with rhinitis at age 5 | |
| UA32462U (ru) | Способ оценки эффективности коррекции нарушений микробиоценоза кишечника у детей младшего возраста с атопическим дерматитом | |
| Alshehri et al. | Saudi experts consensus on diagnosis and management of pediatric functional constipation | |
| Carstens et al. | Neonatal antibiotics in preterm infants and allergic disorders later in life. | |
| Ratanamongkol et al. | Polyethylene glycol 4000 without electrolytes versus milk of magnesia for the treatment of functional constipation in infants and young children: a randomized controlled trial | |
| Kh et al. | Atopic dermatitis and the condition of the intestine in children | |
| Güngör et al. | Effect of maternal depression and environmental factors on infantile colic | |
| Hamed et al. | The effect of probiotics on reducing duration of hospitalization in infants with indirect hyperbilirubinemia | |
| Bertuccioli et al. | Specific prebiotic composition for precision bacterial therapy in patients with irritable bowel syndrome | |
| Sangsupawanich et al. | Relationship between atopic dermatitis and wheeze in the first year of life: analysis of a prospective cohort of Thai children | |
| Ali et al. | Association between anxiety and depression with irritable bowel syndrome in Mosul | |
| Cabana | Early probiotic supplementation for the prevention of atopic disease in newborns-probiotics and the Hygiene Hypothesis | |
| Sharif et al. | PP-036 Spectrum of MRI findings of foetal alcohol syndrome disorders | |
| Ţarcă et al. | Plurimalformative syndrome associating trisomy 18 and omphalocele. Case report and review of the literature | |
| Khamidovna | MEDICAL MANIFESTATIONS AND MODERN VIEWS OF SCIENTISTS OF ALLERGIC REACTIONS IN CHILDREN | |
| Hao et al. | Philippine guidelines on the dietary primary prevention of allergic diseases in children | |
| Gonchar et al. | Trophological status and quality of life in infants administered probiotic enterococci |